We describe a cDNA encoding a serine proteinase inhibitor present in placental tissue and the cytosolic fraction of K562 cells. On the basis of its interaction with thrombin, through which it was discovered, the inhibitor has been operationally named the placental thrombin inhibitor (PTI). Amino acid sequence comparisons suggest that its reactive center is located at , that it lacks a classical N-terminal signal sequence, and that it has the highest degree of similarity to intracellular serine proteinase inhibitors (serpins), such as the human monocyte/neutrophil elastase inhibitor and the equine leukocyte elastase inhibitor.
PHI also resembles these inhibitors in that it contains oxidationsensitive residues adjacent to the reactive site. The PTI cDNA was expressed in rabbit reticulocyte lysate and in COS-7 cells and a 42-kDa protein was produced. Recombinant PTI formed a 67-kDa complex when incubated with thrombin. The ability of native PHI to bind thrombin was destroyed by incubation with iodoacetamide. Analysis of human tissue mRNA indicated that PTI is expressed widely with the highest levels in cardiac and skeletal muscle and placenta. We conclude that PTI is a member of an emerging class of intracellular serpins.
Serine proteinase inhibitors (serpins) are found in a wide variety of plant and animal species (1) . The physiological importance of serpins involved in the regulation of the coagulation, fibrinolytic, and complement systems is well established (2) . The most extensively studied serpins are secreted proteins; however, a small number appear to be intracellular. These belong to the "ovalbumin" class and include plasminogen activator inhibitor 2 and a human elastase inhibitor (3) (4) (5) . Features of these proteins are the lack of classical signal sequences and the presence of oxidation-sensitive residues in close proximity to their reactive sites. Their physiological roles have yet to be established.
We have identified (6) a thrombin-binding serpin present in placenta and in the cytosolic fraction ofthe leukemic cell line K562. We have named it placental thrombin inhibitor (PTI), although this does not necessarily imply a physiological role in thrombin regulation. In this paper we describe the cloning and expression of a cDNA encoding PTIt and suggest that it is a member of an emerging intracellular class of serpins.
MATERIALS AND METHODS
Isolation of PTI cDNA Clones. Total RNA was purified from K562 cells as described (7) . A cDNA template for PCR was synthesized by reverse transcription of -20 Mg of total RNA with 50 units of murine leukemia virus reverse transcriptase (New England Biolabs) and 10 ,g of oligo(dT) primers (8) . PCR primers and a specific probe were degenerate oligonucleotides based on the amino acid sequence of PTI peptides. Sequences of the oligonucleotides were (using the singleletter code for nucleotides at degenerate positions): primer 1 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
(sense), 5'-GGV-AAY-ACH-GCY-CAR-ATG-GC-3'; primer 2 (antisense), 5'-CK-STG-RTC-DGT-DGT-YTC-RTC-3'; probe (sense), 5'-GAY-ATC-CAY-CAR-GGC-TTY-CA-3'. Primers 1 and 2 were used for PCR as described (9) . PCR conditions were as follows for 30 cycles: denaturation, 95°C for 90 s; annealing, 45°C for 90 s; synthesis, 70°C for 180 s. A PCR product of 600 bp was produced and its authenticity was demonstrated by hybridization to the third (probe) oligonucleotide. The PCR product was cloned into the Sma I site of pUC119 (10) for probe preparation and sequence analysis. The 600-bp fragment was labeled with [a-32P]dCTP (NEN DuPont) by random priming (New England Biolabs) and used to screen a human megakaryoblast (MEG-01) AZAP cDNA library (11) and a human placental Agtll cDNA library (CLONTECH). Inserts from positive clones were subcloned into pUC118 (10) . Nucleotide sequence data were generated from denatured double-stranded templates (12) by using the M13 forward and reverse primers and custom-synthesized oligonucleotide primers. Complete sequence data were obtained for both strands using standard dideoxynucleotide sequencing procedures (8) and kits (Sequenase II, United States Biochemical). Sequence analysis was performed using DNASIS Version 7.0 (Hitachi).
Expression of the PTI cDNAs. PTI cDNAs from either the placental (P) or the MEG-01 (M) libraries were subcloned into the EcoRI site of pSVTf (13) . The resulting plasmids (pSVPTI/P and pSVPTI/M) were linearized with Sal I, and PTI mRNA was produced in vitro using T7 DNA-dependent RNA polymerase and then translated in a rabbit reticulocyte lysate system containing [35S]methionine/cysteine (EXPRE35S35S protein labeling mix; NEN DuPont) (14) . pSVPTI/P and pSVPTI/M were also used for expression and studies in COS-7 cells. The cells were transfected with 5 ,ug of plasmid using a DEAE-dextran procedure (8) Triton X-100. The lysates were incubated for 30 min at 37°C, in the presence or absence of 50 nM thrombin. Aliquots were removed and radioactivity was measured in a liquid scintillation counter. The remainder of the samples were then immunoprecipitated with polyclonal antibody to PTI as described (6) . Immunoprecipitated proteins and those produced in the reticulocyte lysate system were analyzed by reduced SDS/ PAGE and fluorography (Amplify, Amersham).
Sensitivity of PTI to Iodoacetamide. K562 cells were grown to confluence as described (6) . The thrombin (6) for 5 min, boiled, and subjected to reduced SDS/PAGE. A sample containing 500 nM purified antithrombin III in 20 mM Tris-HCl, pH 7.4/150 mM NaCl was treated identically to the K562 cell lysate.
Northern Blot Analysis. A membrane containing mRNA from various human tissues was purchased (Human Multiple Tissue Northern Blot; Clontech). By using standard procedures (8) , it was hybridized to a [a-32P]dCTP-labeled PTI cDNA probe. After autoradiography, the membrane was stripped by boiling in 1% SDS and hybridized to an actin cDNA probe supplied with the membrane. Total RNA (7) and/or mRNA (PolyATtract, Promega) was isolated from MEG-01 and K562 cells, separated on a 1% formaldehyde/ agarose gel, transferred to a membrane (Hybond-N+, Amersham), and hybridized to the two probes.
Proteins. Thrombin (15) and antithrombin III (16) were purified as described. Concentrations of proteins were determined by absorbance at 280 nm using extinction coefficients for thrombin (17) of 1.83 mlFmg-l-cm-1 and for antithrombin III (18) of 0.61 ml mg-l cm-1.
Cell Culture. COS-7 cells were grown in Dulbecco's modified Eagle medium containing 20 mM glutamine and 10% (vol/vol) fetal bovine serum (GIBCO-BRL). MEG-01 cells were grown in the same medium lacking glutamine. K562 cells were grown in RPMI 1640 medium (ICN) containing 20 mM glutamine and 10%o heat-inactivated fetal bovine serum. RESULTS Isolation of cDNA Clones Encoding PTI. Amino acid sequencing of peptides derived from purified PTI yielded 11 sequences (6) . Several of these sequences were similar to regions of known serpins, and by sequence alignment, the Nto C-terminal order was deduced. This allowed us to design a PCR-based strategy to obtain a probe for screening cDNA libraries for PTI clones. Degenerate oligonucleotides based on three peptide sequences were synthesized (Fig. 1 ). Oligonucleotides based on the first and third sequences were used as PCR primers and the oligonucleotide corresponding to the second (middle) sequence was used as a probe.
RNA from K562 cells was used for the synthesis ofa cDNA template for the PCR. A 600-bp PCR product that hybridized to the probe oligonucleotide was amplified from the cDNA (data not shown). Amplified fragments from two PCR experiments were cloned into pUC119 and sequenced. Analysis of the nucleotide sequence showed that the fragment contained an open reading frame in which most of the PTI peptide sequences were represented (Fig. 1) . The sequence showed a high degree of similarity to serpins, and searches of DNA and protein data bases [GenBank, Release 73 (September 1992) and SwissProt Release 23 (September 1992)] indicated that it was unique.
To obtain a complete PTI cDNA clone, human cDNA libraries were screened using the 600-bp fragment as a probe. Clones were obtained from a megakaryocytic cell (MEG- CTG TTC TGC GGC CGC T TCC TCT COG TGA GGA CAG GGC AMT CTT GGT GTG CAG CCC CTG TCC TCT GTG TCC CCT GAC ACT CCA 1259  CAG TGT GCC TGC AAC CCA AGT GGC CTT ATC CGT GCA GTG GTG GCA GTT CAG AM TM AGG GCC CAT TTG TGG GAT GCC GCA TTC Proc. Natl. Acad. Sci. USA 90 (1993) Nucleotide and Protein Sequence Analysis of PTI. The nucleotide sequence of the placental PTI cDNA is shown in Fig. 1 . The placental and MEG-01 PTI clones are identical except that the placental cDNA clone is 86 bp longer at the 5' end than the MEG-01 cDNA clone.
Translation ofthe DNA sequence revealed an open reading frame from the beginning ofthe nucleotide sequence, with the first methionine occurring at nt 75 and a termination codon at nt 1203. The open reading frame between the methionine and termination codons encodes a 42-kDa polypeptide, consistent with the previously reported size of PTI [38 kDa (6) ]. Other features of the sequence include a 140-bp 3' untranslated region containing a polyadenylylation signal centered on nt 1314, and potential glycosylation sites at Asn-8, -60, and -80, respectively. The last two residues fall within peptides that we have sequenced and if glycosylated would be expected to generate "blank" signals in the amino acid sequence. As no blanks were observed when these peptides were sequenced, residues 60 and 80 are probably not glycosylated (data not shown).
Although the N terminus of PTI is blocked (6), we are confident that the first methionine represents the start of the PTI coding sequence for the following reasons. (ii) It is in a favorable context for translation initiation according to Kozak's rules (19) . (iii) The codon usage in the open reading frame preceding the methionine does not resemble that found in translated human genes, and the region is predicted by computer analysis to be noncoding. (iv) Expression of a cDNA containing the first methionine yields a unique polypeptide product, whereas expression of a shorter cDNA lacking this methionine gives rise to several polypeptides (see Fig. 2A and below), a pattern commonly seen when the authentic initiation codon is not present and translation commences at inappropriate (internal) methionines. Comparison of the PTI sequence with other serpins revealed that it most resembles members of the ovalbumin group (see Discussion). Of particular interest was the observation that several methionines and a cysteine flank the arginine at the reactive P1 center. This suggested that the function or reactivity of PTI toward thrombin might be destroyed by oxidation or exposure to sulfhydryl-reactive iodoacetamide, as has been observed for the interaction A control pSVPTI/P pSVPTI/M between the human monocyte/neutrophil elastase inhibitor and elastase (4 Fig. 2A) . RNA synthesized from the (shorter) MEG-01 clone lacking the first methionine gave rise to several species of <35 kDa. This resembles the pattern seen when translation is initiated from internal methionines in mRNAs lacking authentic initiation codons. These results show that the placental PTI cDNA encodes a protein of the correct size and suggest that the first methionine in the sequence is the initiation codon. The PTI clones were also expressed in COS cells (Fig. 2B) . After transfection and metabolic labeling, cells were lysed and incorporation of [35S]methionine was measured. Radioactivity varied only slightly between samples (range, 6.7-7.7
x 104 j1l-1). Rabbit anti-PTI antiserum was used to immunoprecipitate PTI from the.lysates. As in the reticulocyte system, the placental PTI clone directed the expression of a 42-kDa protein (Fig. 2B) , whereas the MEG-01 clone expressed a number of smaller proteins (data not shown).
When unlabeled thrombin was added to lysates of transfected COS cells prior to the immunoprecipitation, there was a marked reduction in the 42-kDa polypeptide, and a new species of -67 kDa was apparent. A band corresponding to a 35-kDa polypeptide was also intensified by the addition of thrombin (Fig. 2B) . These results are consistent with the formation of a complex between PFI and thrombin, as we have observed (6) As a control for these experiments, COS cells were transfected with the same expression vector containing a human thrombomodulin cDNA (P.B., unpublished data). A faint 42-kDa species was observed in labeled lysates of these cells after immunoprecipitation with the anti-PTI antibody and SDS/PAGE, and a 67-kDa species appeared when thrombin was present (Fig. 2B ). This suggests that COS cells produce a thrombin-binding protein that cross-reacts with the PTI antiserum. Subsequent experiments along the lines of our original work with PTI (6) showed that 1251-labeled thrombin forms a 67-kDa complex when incubated with COS-cell cytosolic extracts (data not shown).
Even though COS cells apparently synthesize a protein similar to PTI, the greatly increased amounts of both the 42-kDa protein and thrombin-complex-forming activity in PTI-transfected cells are almost certainly due to expression of the human PTI cDNA. Thus with the results of the reticulocyte lysate experiments, this confirms that the PTI cDNA encodes a 42-kDa thrombin-binding protein.
Sensitivity of PTI to Iodoacetamide. Compared to other serpins, PTI has a significant number of cysteine and methionine residues around the reactive site (Fig. 1) . On an intracellular protein, these residues would carry free sulflhydryls. Exposure to an extracellular or oxidizing environment would modify these sites and may impair PTI function. We therefore examined the ability of iodoacetamide, a sulfhydryl alkylating agent, to interfere with complex formation between PTI from K562 cells and 125I-labeled thrombin. Incubation of PTI with 3 mM iodoacetamide for 15 min resulted in a dramatic decrease in complex formed (Fig. 3, lane 3 ) compared with buffer alone (Fig. 3, lane 1) or with 1 mM 2-mercaptoethanol (Fig. 3, lane 2) . In contrast, the interaction of 1251-labeled thrombin and antithrombin III-which lacks oxidation-sensitive residues at the active site-was unaffected by iodoacetamide (Fig. 3, lane 6) .
Tissue Distribution of PIF. A PTI cDNA was used to probe a Northern blot containing mRNA isolated from human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas (Fig. 4) . To compare the amount of mRNA in each sample, the membrane was subsequently hybridized to an actin probe. Although cardiac and skeletal muscle have two forms of actin mRNA, comparison of the levels of the (larger) species present in all tissues showed that the amount of mRNA in each lane of the membrane was similar. In skeletal muscle the smaller actin species is predominant but the amount of the larger form is similar to that seen in other (6) . These are (i) all PTI peptide sequences derived from the purified protein are present in the translated cDNA, (ii) the cDNA directs the synthesis of a 42-kDa protein, and (iii) recombinant PTI forms a 67-kDa complex with thrombin.
PTI is a member of the serpin family of proteins (Fig. 5 ). It has 42 of the 51 conserved residues identified in a survey of 20 serpins (1) , suggesting that it possesses the tertiary structure of a typical serpin. By sequence alignment, the reactive center P1 ofPTI is located at Arg-341. In this respect, it resembles antithrombin III, the prototype thrombin inhibitor, which also has an arginine at the reactive center. However, PTI and antithrombin III differ in the residues occupying the Pi and P2-4 sites; at present we do not know whether this gives rise to significant differences in the kinetics of their interactions with thrombin.
The amino acid sequence ofPFI shows strongest similarity to members of the "ovalbumin branch" of the serpin family, which includes proteins that are predominantly localized intracellularly (Fig. 5) . These are the human monocyte/ neutrophil elastase inhibitor (51% similarity), plasminogen activator inhibitor 2 (48% similarity), and horse leukocyte elastase inhibitor (51% similarity). Key features of these intracellular serpins are their lack of classical signal sequences and their susceptibility to inactivation by thiolreactive reagents (5, 22) . There is no cleavable N-terminal signal sequence evident in the PTI sequence. It also contains three methionine residues and one cysteine residue at the P2-4 
MEDLCVANTLFALNLFKHLAKASPT-ONNL- FLSPWSISSTMAUVYMGSRGSTEDOMAAKVLQF-NEVGANAVTPMTPE   90  100  110  120  130  140  150  160  a1AT - reference to the secondary structure of al-antitrypsin (1) . Serpins compared to PTI were as follows: alAT, al-antitrypsin (20) ; HMNEI, human monocyte/neutrophil elastase inhibitor (5); HLEI, horse leukocyte elastase inhibitor (4); PAI-2, plasminogen activator inhibitor 2 (21) . The reactive site is indicated by an arrow.
that PTI, like plasminogen activator inhibitor 2, is secreted under certain circumstances. If this were the case, the oxidation sensitivity of PTI should limit its action to the immediate vicinity of the site of its release. Northern blot analysis indicates widespread expression of PTI in human tissues and gives rise to the suggestion that it is an important regulator of intracellular serine proteinase activity. However, not enough is known of the normal functions of intracellular serine proteinases or of the intracellular serpins to immediately suggest a specific role for PTI. Identification of specific cell types that produce PTI and investigation of the intracellular location of the protein may suggest a target and function for PTI.
It is possible that PTI interacts with proteins other than serine proteinases. Ray et al. (23) have described a serpin-like protein produced by the vaccinia virus, whose target is probably a cysteine proteinase. Noninhibitory functions for other serpins have also been suggested. Dubin et al. (22) noted that the horse leukocyte elastase inhibitor copurified with thymosin 34. As the latter protein has been shown to regulate actin polymerization (24) , horse leukocyte elastase inhibitor may take part in this process.
